Cannabis Science Inc (fka CBIS)

[dade]

So what is positive to say? I scrutinized very publicly released statement and draw my stance from performance and past precedence.

summary of the past 15 months of operations news. (35 releases I've concluded)
I disregarded and skipped over our companies statements of market conditions, filings, comments regarding other companies or other countries, and fluff.

Below this almost totally reads like a book of fiction - imo

6/18/2009….cbis…announced today that patent filings are expected for two of its key innovations. The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two, Dr. Mary J. Ruwart, Vice President, Research & Development explained. A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to invasion by a competing company
What HAppened?

7/02/2009…cbis...is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.

7/17/2009…cbis…is moving forward confidently under the guidance of its new President & CEO, Dr. Robert Melamede Ph.D. The planning for the companys product line up remains the same, including its FDA fast track initiatives. In the light of recent corporate management changes, Dr. Melamede has begun negotiating with high level industry executives to build a new team with both FDA protocol and research experience to work on Cannabis Sciences extensive product line up and rapid market entry initiatives
Should we discuss this bit of positive intelligence? Because some say, with force, That CBIS is non existent since the latest court findings is entirely retro active ...

7/20/2009….cbis….is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs.
As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.

7/24/2009…cbis…is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming……The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response.

7/27/2009…cbis…to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medici

7/28/2009…cbis…the FDA has provided the Company with documentation to assist the Company to review and plan its initial applications to get its first drug into formal testing.

8/12/2009…cbis…has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time…..The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the www.cannabisscience.com website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.

8/31/2009….cbis….has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.
LOL

9/21/2009…cbis…is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.Robert Melamede stated, “After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge.” Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.
No update?

12/02/2009…cbis…it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares…
nice EOY dilution, thanks.

12/15/2009…cbis…it has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The Company is producing 10-15 different public service announcements in the series. Each one will cover a different topic, such as new break-through research developments, and tracking current and future cannabis medicines going through the FDA process. As well, the series will cover the commercialization of medical marijuana through licensed dispensaries, plus patient interviews about cannabis uses and life experiences, government legal issues and legalization progress tracking, as well as interviews with Doctors, patients, law makers and activists.
No one ever saw 1 of these.....

1/11/2010…cbis…is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."……On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.
Update?

1/25/2010…cbis….released updates to its website today. The website www.cannabisscience.com now integrates its general public communications with recent and future developments in its analytical lab work, clinical research, and commercial production division that are in the process of formalizing the agreements with all the necessary contractors in order to move forward with its medical cannabis clinical trails…….The updated website includes new tools that allow its analytical, clinical research, and commercial production divisions to communicate with the medical cannabis community, survey specific populations, and receive feedback from patients, partners, and investors. The information gathered through its site surveys and forums will help guide its clinical research as well as contribute to scientific databases, and our live blog will allow the community to check in on its progress.
The blog and website are rotten with Nike Shoe spam....

2/09/2010….cbis….it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market….Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
Didn't Happen?

2/22/2010….cbis….progress in its Analytical Lab Division at Cannabis Science. Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., explained, " As a patient oriented company located in a state with effective medical marijuana laws, we are able to study the medical production and use of cannabis in a variety of modalities. At the core of this research, we are working with patients producing top grade medical cannabis as the starting point for extracts and formulations to treat the many disease states that cannabinoids positively impact. Efficient, stable propagation and quality control of the starting material and downstream processes are essential to this progress."There are several integral and interdependent facets of this approach: Lab Division:I. Propagationa. Traditional Cloning, Micropropagation & Extensive Seed BankII. QC & Analyticsa. Genetic QC such as Fingerprintingb. Biochemical & Contaminant QC including HPLC and GCIII. Extracts and FormulationsIV. Final Product Testing a. Local clinical Trials b. FDA Clinical Trials
This is important boys and girls because our company has an analytical lab, much like the bat cave it doesn't exist....

2/25/2010…cbis….is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.
Fluff that kept us longs biting......

5/7/2010….cbis….has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.

5/12/2010….cbis….it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system.

5/13/2009…cbis…it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines….Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."
Did this happen? no update ever?

5/24/2010…cbis….it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.
:(

6/01/2010…cbis…is pleased to announces preliminary patent disclosures and major steps towards the acquisition of a private company for the development of the new patentable products that should facilitate broad acceptance of specific Cannabis Science pharmaceutical products designed for the treatment of chronic pain, Post Traumatic Stress Disorder (PTSD) and other critical illnesses addressed throughout the www.cannabisscience.com company website….Melamede, PhD., Cannabis Science President and CEO, reported, "We have been negotiating to purchase a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. As a faculty member at the University of Colorado at Colorado Springs, I have filed a preliminary patent disclosure with the University of Colorado regarding additional new technology that Cannabis Science intends to develop through the targeted private company acquisition. As a part of this process, we are hiring a distinguished patent attorney to help with the University disclosure and ultimate patent filings. We are also using our FDA consultants to advise on the technology's FDA approval pathway because we foresee several new FDA pharmaceutical products that can be derived from this deal."
This was the last fluff we saw mention of FDA jibber jabber......

6/17/2010…cbis….is pleased to report that it is acquiring one of the leading medical marijuana providers and pioneers in the industry in the state of Montana; Montana Pain Management, Inc. (MPM) (www.montanapm.com). MPM is a for-profit clinic which, in conjunction with duly licensed caregivers, provides a full range of cannabis therapeutics and other services to its patients throughout the state of Montana
:(
6/29/2010….cbis….reports that it has begun the process of expanding the internal production and research capabilities of Missoula medical cannabis provider, Montana Pain Management (MPM), which Cannabis Science acquired earlier this month.
:(

7/06/2010….cbis….is proud to announce that Dr. Arturo Morales of Hartford, Connecticut, has agreed to join its Scientific Advisory Board. Dr. Robert Melamede PhD., Cannabis Science President and CEO noted, "We are extremely honored to have such a distinguished doctor join our Scientific Advisory Board. Dr. Morales has said that he wishes to become a 'successful advocate in the struggle to remove restrictions on the medical uses of cannabis.' We are delighted to welcome him to our team.
Does Dr. Morales still work here? DOes he have any interest in CBIS?

7/08/2010….cbis….it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.
Ah yeah, were still waiting for an update in this....

8/12/2010….cbis….announced today that it has executed a Joint Venture Agreement with Smokefree Innotec Inc. (Pink Sheets:SFIO). The objective of the joint venture is to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products. Under the joint venture, Smokefree Innotec, Inc. will provide its high-tech smoke-free vapor technology devices, and Cannabis Science will provide all the medical cannabis extract formulations. Both parties equally share in the revenues derived from this Joint Venture.
And does Rockbrook with full latitude have claim to this JV?

8/18/2010….cbis….reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement that he and Montana Pain Management, Inc. ("MPM") had signed with Cannabis Science. Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, "We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse.
CBIS has not attempted to update or upgrade corporate non compete clauses....

8/18/2010….cbis….signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
Is this retroactive and apply to future FDA drugs? If so, ouch....

8/18/2010…cbis….Thomas Schroepfer, CEO, (www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, “Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations.”
I ask how will they get product (marijuana) from State to State? What were the terms and conditions of this JV? Will rockbrook intercept or have claim to proceeds?

8/24/2010….cbis….Dr. Robert Melamede, PhD., whose mother was German, remarked, "Germany's recognition of the medical value of cannabis coincides with our plans for expansion into Europe. We hope that America is not going to squander its lead in medical cannabis research, but Cannabis Science will certainly work with German and other European researchers and clinicians to develop medical cannabis products that meet the needs of patients around the world."
LOL...we publicly released heritage lineage...

8/30/2010…cbis….is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges…..cbis…..is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex® in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex® is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.

9/09/2010….cbis….is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.
What progress; Fill us in please...

9/13/2010…cbis….announces the formation of a new LLC, CANNABIS SCIENCE SMOKEFREE JV LLC, which has started testing various medical cannabis formulations for possible early JV product release entering the potential multi-billion medical cannabis market.

9/20/2010….cbis….is pleased to announce that its Board of Directors have begun investigating the corporate and legal requirements required to issue dividends to shareholders to create a new class of common shares. …..The company is in advanced negotiations with several groups pursuing funding opportunities for up to $5 million between $1.00 and $3.00 per new share. ……The proceeds will be used to fund FDA clinical trials, acquisitions, and further product research and development.